

Haematologica  
HAEMATOL/2018/195818  
Version 4

Deep targeted sequencing of TP53 in chronic lymphocytic leukemia:  
clinical impact at diagnosis and at time of treatment.

Christian Brieghel, Savvas Kinalis, Christina W. Yde, Ane Y. Schmidt,  
Lars Jønson, Michael A. Andersen, Caspar da Cunha-Bang, Lone B.  
Pedersen, Christian H. Geisler, Finn C. Nielsen, and Carsten U.  
Niemann

Disclosures: 1. CN has received funding from the Danish Cancer Society and the Novo Nordisk Foundation. CB has received funding from Copenhagen University Hospital, Rigshospitalet and Arvid Nilsson's Fund. FCN, LJ, SK, CWY, AYS, MAA, CdC, LBP, and CG declare no competing financial interests. 2. CN has received grants/consultancy fees from Abbvie, Janssen, Gilead, Roche and Novartis outside of this study. FCN serves on an advisory board for Qiagen outside of this study. Outside of this study LJ is currently employed by Roche. During this study, LJ has only been affiliated as a researcher at Copenhagen University Hospital, Rigshospitalet prior to his employment at Roche. CB, SK, CWY, AYS, MAA, CdC, LBP, and CG declare no competing financial interests outside of this study. 3. All authors declare no planned, pending or issued patents or copyright.

Contributions: Conception and design: Christian Brieghel, Carsten Niemann, Lone Bredo Pedersen, Lars Jønson, Finn Cilius Nielsen. Provision of study materials: Christian Brieghel, Carsten Niemann, Christian Geisler, Lone Bredo Pedersen, Caspar da Cunha-Bang. Collection and assembly of data: Christian Brieghel, Savvas Kinalis Data analysis and interpretation: Christian Brieghel, Savvas Kinalis, Carsten Niemann, Ane Yde Schmidt, Christina Westmose Yde, Michael Asger Andersen, Caspar da Cunha-Bang. Manuscript writing: Christian Brieghel, Carsten Niemann. Final approval of manuscript: All authors.